GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW logo

„GW is dedicated to developing Epidiolex for Dravet syndrome as rapidly as possible. As such, the start of the first Dravet syndrome Phase 3 trial is a significant milestone for our Company and we are on track to start the second Phase 3 trial very shortly,“ stated Justin Gover, GW’s Chief Executive Officer. „We look forward to working with epilepsy physicians across the United States to execute this program with the objective of submitting a New Drug Application for Epidiolex to the FDA in mid-2016.“

For the whole article click HERE